ClinicalTrials.gg
RecruitingNCT04741438RAR-ImmuneUpdated Aug 30, 2023

Efficacy of the Combination of Nivolumab and Ipilimumab as a Treatment in Patients With Sarcoma of Rare Subtype

A Phase 3 interventional study of Nivolumab and IPILIMUMAB and Pazopanib Oral Tablet [Votrient] in Sarcoma, sponsored by Centre Leon Berard. Recruiting at 13 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-08-30.

Sponsored by Centre Leon Berard · Phase 3, Interventional, and Treatment

How we know · 7 judgments

From the registry’s dates

  • Primary completion was expected by Feb 2025, 1 year 9 months ago, but the record still lists the study as recruiting.
  • Started Mar 2021; still recruiting 5 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies testing nivolumab in Sarcoma — 6 open to participants now, 11 under way, 1 of them phase 3. Nivolumab · Sarcoma.

Planned enrollment
7th of 19
96 · median 60
Started
2021
with 1 other
Phase 3
Only one
of the 19
Primary completion
2025-02
later than 1 of 10 live
Registered
16th of 19
by date
Lead sponsor
1 of 19
Centre Leon Berard

Among the 19 studies testing nivolumab in Sarcoma, this one is the 7th largest by planned enrollment, is one of 2 that started in 2021, is the only one in phase 3, reaches primary completion later than 1 of the 10 other live ones, and was the 16th registered.

Sarcoma

1,610 studies on the registry are indexed under Sarcoma; 367 are open to participants now.

Browse Sarcoma studies →

Open to participants now

6 of the 19 studies testing nivolumab in Sarcoma are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 302 Sarcoma studies recruiting now, 192 (64%) set no upper age limit and 83 (27%) stop at 75 or younger; 94 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing nivolumab in Sarcoma, or all of them as a file.
02

Study summary

This is a randomized open label study, with 2 arms treatments conducted in patients with metastatic or unresectable advanced sarcoma of rare subtype; previously treated by anthracycline-based regimen except for whom standard therapy does not exist or is not considered appropriate by the Investigator.

In the experimental arm, patients will receive the combination of Nivolumab + Ipilimumab for a maximum of 24 months, whereas in the control arm, patients will receive Pazopanib alone.

The purpose of the study is to know if the combination of nivolumab + ipilimumab can be more efficient than Pazopanib in terms of Progression-Free Survival.

Read the detailed description

This is a randomized open label, comparative, prospective, multicentre phase III study.

The patients who meet the eligibility criteria will be randomly assigned (1:1) into one of the following treatments groups:

  • Experimental arm: Nivolumab + Ipilimumab (24 months maximum)
  • Control arm: Pazopanib alone (24 months maximum)

A randomization procedure will be used to obtain a balanced distribution of stratifications factors:

  • The number of previous lines of treatment in advanced/metastatic setting: ≤1 line or >1 line (a treatment line is defined as a treatment initiation whatever the reason)
  • The lymphocytes count at baseline: \<1 g/L or ≥1 g/L.

After their eligibility has been confirmed, patients will be treated with:

  • The combination of Nivolumab + Ipilimumab for 4 cycles. After completion of 4 cycles with Ipilimumab, patients continue receiving nivolumab IV (480 mg Q4W) in the absence of disease progression or unacceptable toxicity. A cycle is defined as a 6-weeks period.
  • Or Pazopanib until disease progression or unacceptable toxicity. The planned treatment duration in both arm is maximum 24 months.

After the completion of treatment, patients will be followed up within 30 days after the last study treatment administration. The survival and disease status will be updated for all patients at the time of the end of the study.

The overall end of the study will be the Last Patient Last Visit (LPLV), defined as the End Of Treatment (EOT) visit of the last active patient.

03

Conditions studied

  • Sarcoma

Browse trials for

Keywords

  • Sarcoma of rare subtype
  • Metastatic sarcoma
  • Unresectable advanced sarcoma
  • Nivolumab
  • Ipilimumab
  • Randomization
  • Pazopanib
  • Progression free-survival
  • Best Overall Response
  • Objective response rate
  • Duration of response
  • Time to treatment failure
  • Overall survival
  • Quality of Life
  • Tolerance profile
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

I1. Age ≥ 18 years at the day of consenting to the study;

I2. Only confirmed sarcoma of rare subtype, defined as one of the following subtypes:

  • Angiosarcoma (AS)
  • Alveolar Soft Part Sarcoma (ASPS)
  • Clear Cell Sarcoma (CCSA)
  • Desmoplastic Small Round Cell Tumour (DSRCT)
  • Sclerosing Epithelioid Fibrosarcoma (SEF)
  • Perivascular Epithelioid Cell Tumour (PEComa)
  • Intimal sarcoma (IS)
  • Extraskeletal Myxoid Chondrosarcoma (EMC)
  • Solitary Fibrous Tumour (SFT)
  • Epithelioid HemangioEndothelioma (EHE)
  • Inflammatory Myofibroblastic Tumour (IMT)
  • Epithelioid sarcoma (ES)
  • FibroSarcoma (FS)
  • SMARCA-4 deficient sarcoma
  • Malign Peripheral Nerve Sheath Tumours (MPNST)
  • Chordoma;

I3. disease or unresectable locally advanced that is resistant or to standard therapy or for which standard therapy does not exist or is not considered appropriate by the Investigator;

I4. as per the version 1.1;

I5. Previously treated with anthracycline-based regimen except for whom standard therapy does not exist or is not considered appropriate by the Investigator: inclusion in is allowed (randomisation will be stratified according to the number of previous treatment lines);

I6. Performance Status () of 0 or 1;

I7. Patients must have an adequate organ and bone marrow function at baseline;

  • (ANC) ≥ 1.0 x 10 G/L
  • ≥ 100 x 10 G/L
  • ≥ 9 g/dL (without transfusion within 7 days)
  • Serum creatinine OR Calculated as per or CKD-EPI formula ≤ 1.5 (ULN) OR ≥ 40 mL/min /1.73m2
  • Serum total ≤ 1.5 ULN OR Direct bilirubin ≤ ULN for patients with total bilirubin levels > 1.5 ULN (except for patients with Gilbert disease for whom a total serum bilirubin ≤ 3ULN is acceptable).
  • and ALT ≤ 3 ULN
  • (INR) and activated Partial Thromboplastin Time (aPTT) ≤ 1.5 ULN

I8. Women of must have a negative serum pregnancy test within 7 days before C1D1.

I9. Women of childbearing potential must agree to use 1 highly effective form of from the time of the negative pregnancy test up to 3 months after the last dose of study drugs.

I10. Ability to understand and willingness for follow-up visits;

I11. Covered by a medical insurance;

I12. Signed and dated document indicating that the patient has been informed of all aspects of the trial prior to enrolment.

Exclusion criteria

Exclusion Criteria:

E1. Concurrent use of any other approved or antineoplastic agent;

E2. Prior or concurrent treatment with any antibody targeting PD1, PDL1, PDL2 or CTLA4;

E3. Prior treatment with pazopanib;

E4. Symptomatic, untreated, or actively progressing central nervous system (CNS) .

Note:

  • Asymptomatic patients with treated CNS lesions are eligible.
  • Asymptomatic patients with newly detected at screening are eligible for the study after receiving radiotherapy or surgery, with no need to repeat the screening brain scan;

E5. Patients using, or requirement to use while on the study, or not respecting the minimal of medications listed below:

Forbidden concomitant medications and minimal wash-out period before Cycle 1 Day1

  • Any approved anti-cancer systemic treatment including chemotherapy, hormonotherapy, biological therapy, or immunotherapy : 2 weeks
  • Any investigational agents : 4 weeks
  • Radiotherapy Note: palliative radiotherapy on non-target lesions is allowed. : 3 weeks
  • Surgery
  • Major surgical procedure, open , or significant traumatic injury : 4 weeks
  • Abdominal surgery, abdominal interventions or significant abdominal traumatic injury : 60 days
  • . Note: Influenza vaccination should be given during influenza season. Patients must not receive live attenuated influenza vaccine (e.g., FluMist®) : 4 weeks
  • Systemic immunostimulatory agents, including but not limited to IFN-α, IFN-γ, or IL-2 : 4 weeks
  • medication (including but not limited to , cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-TNF-alpha agents) with the exceptions of intranasal, inhaled, or topical corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone (or 0.1mg/kg for pediatric patients), or an equivalent corticosteroid :2 weeks
  • P-gp inhibitors : None
  • Strong or moderate inhibitors of : None
  • Strong CYP3A4 inducers : None
  • Oral or IV antibiotics :2 weeks

Note: Patients receiving prophylactic antibiotics (e.g., to prevent a urinary tract infection, pneumocystis or exacerbation) are eligible.

E6. History of disease including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barre syndrome, multiple sclerosis, vasculitis, or glomerulonephritis with the following exceptions:

  • patients with a history of autoimmune-related hypothyroidism who are on stable thyroid replacement hormone therapy,
  • patients with controlled Type 1 diabetes mellitus,
  • patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis would be excluded) are eligible provided that they meet the following conditions:

    • Rash must cover less than 10% of body surface area (BSA).
    • Disease is well controlled at baseline and only requiring low potency topical steroids.
    • No acute exacerbations of underlying condition within the previous 12 months requiring psoralen plus ultraviolet A radiation (PUVA), methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, high potency or oral steroids;

E7. Patients with , active B or C hepatitis infection, or any other active infection.

E8. Patients with active tuberculosis;

E9. Prior bone marrow transplantation or solid organ transplant for another in the past;

E10. History of idiopathic pulmonary fibrosis (including pneumonitis), drug-induced pneumonitis, organizing pneumonia (i.e. bronchiolitis obliterans, cryptogenic organizing pneumonia), or evidence of active pneumonitis on screening chest CT scan;

E11. Patients with a high-risk of hemorrhage or history of coagulopathy;

E12. Any to nivolumab, to ipilimumab or to pazopanib according to the Summary of Product Characteristics of each drug;

E13. History of other malignancy other than study disease (except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix) unless the patient has been free of disease for at least 3 years;

E14. Patient under tutorship or curatorship or deprived of liberty;

E15. Pregnant or breast-feeding woman

Terms in these criteria, in plain language(33)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
96 participants (estimated)

Study arms

  • Experimental
    Arm A

    Arm A (Experimental arm). * Nivolumab 3 mg/kg * Ipilimumab 1 mg/kg

    Drug: Nivolumab and IPILIMUMAB

  • Active comparator
    Arm B

    Arm B (Control arm). Pazopanib 800 mg/day

    Drug: Pazopanib Oral Tablet [Votrient]

Interventions

  • DrugNivolumab and IPILIMUMAB

    Drug pages: NivolumabStudies of NivolumabNivolumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · IpilimumabStudies of IpilimumabIpilimumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The combination of Nivolumab+Ipilimumab will be given to patients as follows: * Nivolumab: 3 mg/kg IV over 30 minutes every 2 weeks for 4 cycles. * Ipilimumab 1 mg/kg IV over 60 minutes every 6 weeks for 4 cycles. After completion of 4 courses with ipilimumab, patients continue receiving nivolumab IV at the dose of 480 mg Q4W in the absence of disease progression or unacceptable toxicity for a maximum of 18 months. Nota Bene: A cycle is defined as a 6-weeks period. The planned treatment period is 24 months Nivolumab and Ipilimumab must be injected the same day every 6 weeks (Q6W). In case of toxicity, dose will be delayed, but will not be reduced.

  • DrugPazopanibStudies of PazopanibPazopanib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Treatment by pazopanib 800 mg/day per os, continuously during a maximum 24 months. In case of toxicity, dose will be delayed and reduced.

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS)

    The Progression-Free Survival defined as the time from the date of randomisation to the date of first documented progression or death due to any cause. Patients who have not progressed or died at the time of analysis will be censored at the time of the latest date of assessment.

    Time frame: up to 36 months

Secondary outcomes

  1. Best Overall Response (BOR)

    The Best Overall Response will be defined as the best among all overall responses during the trial.

    Time frame: up to 36 months

  2. Objective Response Rate (ORR)

    The Objective Response Rate will be defined as the proportion of patients with a best overall response of Complete Response (CR) or Partial Response (PR) during the trial.

    Time frame: up to 36 months

  3. Duration of Response (DOR)

    in the patients whose BOR is either CR or PR, the DOR will be defined as the time from the date of first documented tumour response to the date of first documented disease progression or death due to underlying cancer. Patients with no event at the time of the analysis will be censored.

    Time frame: up to 36 months

  4. Time to Treatment Failure (TTF)

    The Time to Treatment Failure will be defined as the time from the date of randomisation to the date of permanent study treatments discontinuation (any cause, including disease progression, treatment toxicity, adverse event, start of any new anticancer therapy, withdrawal of consent and death). Patients without treatment failure at the time of the analysis will be censored at the date of last tumour

    Time frame: up to 36 months

  5. Overall Survival (OS)

    The Overall Survival will be defined as the time from the date of randomisation to the date of death due to any cause. Any patient not known to have died at the time of analysis will be censored based on the last recorded date on which the patient was known to be alive.

    Time frame: up to 36 months

  6. Quality of Life (QoL)

    The Quality of Life will be assessed using the EORTC QLQ-C30 questionnaire.

    Time frame: up to 36 months

  7. Tolerance profile

    The Tolerance profile will be described through the incidence and severity of drug-related AEs according to the Common Terminology Criteria for Adverse Events (CTCAE) (v5.0)

    Time frame: up to 36 months

07

Study locations

10 of 13 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2021 (actual). Primary completion is estimated for Feb 2025, 47 months after the start.

Of 24 phase 3 interventional studies under Sarcoma, half reached primary completion within 105 months of starting (the median), counting those still running; a quarter within 50 and three quarters within 155. This study's planned 47 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2021
First posted
Feb 5, 2021
StartActual
Mar 30, 2021
Primary completionEst.
Feb 2025
CompletionEst.
Aug 2025
Last update
Aug 30, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 30, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04741438
Lead sponsor
Centre Leon Berard
Responsible party
Sponsor
First posted
Feb 5, 2021
Start date
Mar 30, 2021
Primary completion
Feb 2025 (estimated)
Completion
Aug 2025 (estimated)
Last update
Aug 30, 2023

Study contacts

Séverine METZGER
Contact
severine.metzger@lyon.unicancer.fr
+33(0)478782786

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nivolumab · Ipilimumab

Start the discussion